NASDAQ:VBIV - VBI Vaccines Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.25
  • Forecasted Upside: 151.00 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$2.49
▼ -0.23 (-8.46%)
1 month | 3 months | 12 months
Get New VBI Vaccines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VBIV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VBIV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.25
▲ +151.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for VBI Vaccines in the last 3 months. The average price target is $6.25, with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 151.00% upside from the last price of $2.49.
Buy
The current consensus among 4 polled investment analysts is to buy stock in VBI Vaccines. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2019
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2019
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/29/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/27/2020OppenheimerReiterated RatingBuy$8.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/26/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$8.00 ➝ $9.00High
i
7/22/2020Raymond JamesBoost Price TargetOutperform$3.00 ➝ $8.00High
i
6/29/2020BMO Capital MarketsReiterated RatingBuy$4.00Low
i
6/23/2020OppenheimerBoost Price TargetOutperform$5.00 ➝ $8.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
5/7/2020OppenheimerReiterated RatingBuy$5.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
3/6/2020Canaccord GenuityReiterated RatingBuy$4.00High
i
11/14/2019Raymond JamesInitiated CoverageOutperform$3.00High
i
6/19/2019OppenheimerSet Price TargetBuy$5.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/18/2019BMO Capital MarketsLower Price TargetOutperform$5.00Low
i
2/26/2019OppenheimerSet Price TargetBuy$9.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
1/16/2019OppenheimerInitiated CoverageOutperform$9.00 ➝ $9.00High
i
7/27/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$13.00 ➝ $12.00High
i
5/10/2018BMO Capital MarketsBoost Price TargetOutperform$11.00 ➝ $13.00Low
i
3/23/2018Noble FinancialReiterated RatingBuyHigh
i
11/15/2017BMO Capital MarketsInitiated CoverageOutperform$11.00N/A
i
11/1/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$10.00N/A
i
7/31/2017Noble FinancialReiterated RatingBuyHigh
i
5/15/2017Noble FinancialReiterated RatingBuyLow
i
5/5/2017Noble FinancialReiterated RatingBuyLow
i
10/10/2016LaidlawInitiated CoverageBuy$6.00N/A
i
7/26/2016LADENBURG THALM/SH SHInitiated CoverageBuyN/A
i
(Data available from 11/25/2015 forward)
VBI Vaccines logo
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.49
$2.46
$2.76

50 Day Range

MA: $2.64
$2.15
$3.07

52 Week Range

Now: $2.49
$0.64
$6.93

Volume

7,954,225 shs

Average Volume

9,554,975 shs

Market Capitalization

$602.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93